CDK9 inhibitorenitociclib and CDK9 are not unknowns, but it is great to see it being used in logical combos. Seeing some synergy that would be unlikely by chance in a Phase 1 trial of a handful of patients is encouraging.
Is there a leak that explains why the stock has been on a tear, or is it just that everyone is jumping on a rising stock, and only the early January bump actually has a reason.
In any case, the company will want to do a raise at some point this year, so expect a string of news once they decide to go for it.